

Supporting information






Figure 1 Viability of PC12 cells treated with A β ₂₅₋₃₅, (*n* = 6 for each group). The cells were treated with A β ₂₅₋₃₅ at the dosage of 25 μ M, 35 μ M, 45 μ M, 55 μ M, 65 μ M for 48 h, after that, MTT assay used for measuring cell viability. *Comparing with control group, *P* < 0.05.




(A)




(B)

Figure 2 Viability of PC12 cells pretreated with VE and DHA, (*n* = 6 for each group). The cells were pretreated with VE (3.125 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM) and DHA (3.125 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM) for 4h, after that, 50 μM Aβ₂₅₋₃₅ was added into the culture medium for another 24 h (A) or 48 h (B) incubation. MTT assay was used for measuring cell viability. *Comparing with control group, *P* < 0.05; #: comparing with Aβ₂₅₋₃₅ treatment group, *P* < 0.05.



(A)



(B)

Figure 3 Viability of PC12 cells pretreated with VE+DHA, ($n = 6$ for each group).

The cells were pretreated with VE+DHA (6.25 μ M VE +12.5 μ M DHA, 6.25 μ M VE + 25 μ M DHA, 3.125 μ M VE +12.5 μ M DHA, 3.125 μ M VE +25 μ M DHA) for 4h, after that, 50 μ M A β_{25-35} was added into the culture medium for another 24 h (A) or 48 h (B) incubation. MTT assay was used for measuring cell viability. *Comparing with control group, $P < 0.05$; #: comparing with A β_{25-35} treatment group, $P < 0.05$; a: comparing with A β_{25-35} +VE6.25+DHA 25 μ M group, $P < 0.05$.